Premium
Active alpha 2 and beta adrenoceptors in lymphocytes from patients with chronic lymphocytic leukemia
Author(s) -
Goin Juan C.,
SterinBorda Leonor,
Borda Enri S.,
Finiasz Marta,
Fernandez J.,
De Bracco Maria M. E.
Publication year - 1991
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910490205
Subject(s) - endocrinology , medicine , prazosin , chronic lymphocytic leukemia , dihydroalprenolol , receptor , agonist , adrenergic receptor , yohimbine , alpha (finance) , population , biology , antagonist , chemistry , leukemia , partial agonist , construct validity , nursing , environmental health , patient satisfaction
A single population of alpha 2 adrenoceptors was characterized in intact B lymphocytes from patients with chronic lymphocytic leukemia (B‐CLL) by binding and saturation studies with 3 H labelled yohimbine and by competition studies with alpha adrenergic antagonists. While the affinity of B‐CLL alpha 2 adrenoceptors was low (K D : 9.81 nm‐20.98 nm), each cell expressed a large number of receptors. No binding of the alpha 1 adrenoceptor antagonist prazosin was observed and the binding properties of beta adrenergic receptors (assayed with 3 H‐labelled dihydroalprenolol), were similar to those described for normal lymphocytes. Reaction of B‐CLL with the beta adrenergic agonist isoproterenol raised the levels of cAMP in 11/13 patients tested, and in 8 of these, incubation with the alpha 2 adrenergic agonist clonidine prevented the effect and reduced the basal cAMP levels. The presence of active alpha 2 adrenoceptors on B‐CLL lymphocytes may be involved in the regulation of metabolic pathways that affect cell functions and favor neoplastic growth.